A Different Hormone Target: FGF21

The body uses hormones as chemical messages, and one of them, fibroblast growth factor 21, or FGF21, is emerging as a weight-loss signal that works by burning more energy, not mainly by making animals eat less. (inside.ouhsc.edu) University of Oklahoma researchers reported on April 1, 2026 that FGF21 acts in the hindbrain, a lower brain region that helps control metabolism and appetite. Their paper was published in *Cell Reports* as “Pharmacological administration of FGF21 reverses obesity through a parabrachial-projecting neuron population in the hindbrain.” (inside.ouhsc.edu) (cell.com) The team said FGF21 signals specifically to the nucleus of the solitary tract and the area postrema, two hindbrain structures that then relay the signal to the parabrachial nucleus. In the study, that circuit was necessary for FGF21’s metabolic effects and body-weight reduction in mice. (inside.ouhsc.edu) (cell.com) That puts FGF21 in some of the same brain territory implicated in glucagon-like peptide-1, or GLP-1, drugs, including area postrema and nucleus of the solitary tract circuits in the hindbrain. A 2024 *Nature* study found hindbrain GLP-1 receptor neurons are required for the weight-loss effects of GLP-1-based obesity drugs, with nucleus of the solitary tract neurons linked to satiety and area postrema neurons linked to aversion. (nature.com) But the mechanisms are not the same. The Oklahoma group said GLP-1 lowers food intake, while FGF21 raises metabolic rate, meaning the body uses more energy even without the same primary appetite effect. (inside.ouhsc.edu) That distinction lands in an obesity field dominated by drugs that are best known for making people feel full sooner and eat less. In a 2024 *Science* paper, researchers reported that GLP-1 receptor agonists increased “preingestive satiation” in people with obesity and traced that effect to dorsomedial hypothalamus neurons in mice and human tissue. (pmc.ncbi.nlm.nih.gov) FGF21 is not a new molecule. Drug developers have already been testing FGF21-pathway medicines for metabolic dysfunction-associated steatohepatitis, or MASH, a fatty liver disease, and older animal work has also suggested FGF21 can lower weight without reducing food intake. (inside.ouhsc.edu) (nature.com) The trade-off is that FGF21 analogs have had side effects of their own, including gastrointestinal problems and, in some cases, bone loss, according to the Oklahoma researchers. Potthoff said mapping the exact circuit could help in designing more targeted drugs with fewer unwanted effects. (inside.ouhsc.edu) For now, the new result is a mouse-mechanism study, not a new approved treatment. The next step the researchers flagged is testing whether the same hindbrain circuit also explains how FGF21 and related drugs might reverse MASH as well as reduce body weight. (inside.ouhsc.edu)